International Clinical Trial: A Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Antitumor Efficacy of YXC-001 in Participants with Advanced Solid Tumors

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133398) titled 'A Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Antitumor Efficacy of YXC-001 in Participants with Advanced Solid Tumors' on Sept. 25.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Shanghai Chest Hospital

Condition: Advanced solid tumors

Intervention: Phase Ia dose?escalation cohort:YXC-001, dose escalation (0.5-6 mg/kg), administered by intravenous infusion. It is given once every two weeks, and a four-week period constitutes one cycle.

Recruitment Status: Not Recruiting

P...